CrystagenКристаген
A short-peptide product described in institute reports as containing glutamate, aspartate and proline. The reports do not establish that the tested product was chemically identical to isolated Glu–Asp–Pro (EDP).
What the studies found
Comparison in people · 2006
Crystagen after radiation exposure: Medical Center clinical report
In the low-dose radiation subgroup, CD4-positive cells were 32.1% after Crystagen plus usual care versus 29.7% after usual care alone. The table marks the change from baseline, with no reported between-group test.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.
Design 40 received Crystagen plus conventional therapy and 30 received conventional therapy alone. The reported oral regimen was one to three capsules two to three times daily for 15–20 days. Table 2 covers the low-dose radiation subgroup (20 treated, 15 comparator).
- CD4-positive cells in the low-dose radiation subgroup
- 32.1 ± 1.8% with Crystagen vs 29.7 ± 2.4% with conventional care. Shared baseline 26.3 ± 2.4%.The Crystagen value is marked p < 0.05 versus baseline.
- CD3-positive cells in the low-dose radiation subgroup
- 53.3 ± 2.2% with Crystagen vs 49.3 ± 2.3% with conventional care. Shared baseline 45.1 ± 2.1%.The Crystagen value is marked p < 0.05 versus baseline.
- IgG in the low-dose radiation subgroup
- 15.2 ± 1.5 g/L with Crystagen vs 15.4 ± 1.4 g/L with conventional care. Shared baseline 15.1 ± 1.2 g/L.The table gives no significance mark for IgG.
Important limitations
- The report gives one shared baseline column and leaves allocation and masking unspecified. The low-dose radiation table covers 20 treated patients and 15 conventional-care patients. The clinical product is insufficiently characterized to establish equivalence with synthetic EDP.
- The report uses a shared baseline and gives no direct between-group statistical test for these outcomes.
Reports on clinical studies of CYTOMAX and CYTOGEN products; PDF page 109 · Institute report / commercial reproduction
Observational study · 2013
Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency
Study of multiple preparations
- IgG
- 1,202.27 → 1,445.20 mg/dLBefore and after the combination.p<0.01
- CD4 cells
- 501.96 → 569.33 cells/µLp<0.01
- IgM
- 126.56 → 132.46 mg/dLp<0.01
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
More reported outcomes
- CD3 and CD8 cells
- 963.01 → 1,088.78 and 389.72 → 438.10 cells/µLp<0.01 and p<0.05, respectively
- IgA, CD19 and CD4/CD8 ratio
- No statistically significant changep>0.05
- Author-defined overall outcome
- 105/150 good, 45/150 fairNo untreated group for this rating.
Study notes · methods, sources and limitations
Participants or model 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
Design The researchers compared immunoglobulins and lymphocyte markers before and after the 20-day regimen. Tables show paired assessment denominators of 150. The reference laboratory column is a population benchmark.
Important limitations
- This was a before-and-after study of three products with no concurrent untreated group. Individual product effects and effects on infection risk remain uncertain. Program 33 reports 300 participants across two clinical series. The relationship between the two participant lists remains unverified.
Journal of Tropical Science and Technology. 2013;(2):78–84. · Publication record
Observational study · 2012
Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans
Study of multiple preparations
- International Prostate Symptom Score
- 20.94 ± 8.49 → 8.46 ± 2.78p<0.01
- Urinary flow
- 4.9 ± 2.3 → 9.1 ± 2.5 mL/sp<0.001
- Urinary symptom quality-of-life item
- 4.10 ± 1.01 → 2.53 ± 0.61p<0.001
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
More reported outcomes
- Severe urinary symptoms
- 61/150 → 14/150IPSS ≥20. The paper reports 40.7% → 9.3%.
Study notes · methods, sources and limitations
Participants or model 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
Design Prospective, within-person comparison of urinary symptoms, quality of life and urine flow before and after adjunctive treatment. All reported denominators below are 150 at each assessment.
Important limitations
- There was no concurrent untreated comparator or single-product arm. The results cover the combination. The tested Veziliut lot and its peptide content remain unclear. The two 150-person publications are part of the same parent program, and participant overlap remains unverified.
Journal of Tropical Science and Technology. 2012;(1):85–93. · Publication record
About Crystagen
Research background
Crystagen is an oral peptide preparation studied for immune markers after radiation exposure. Experimental work with the Glu–Asp–Pro (EDP) tripeptide has its own formulation and methods.
More study findings
Lab research · 2016
Vladonix, Endoluten and other peptides in cultured human blood cells
Findings for this preparation
- Crystagen and Cortexin · lysate IL-18
- 75.10 and 60.02 vs 39.06 pg/mLEach preparation versus saline. Crystagen’s printed interval is inconsistent.p = 0.004 and p = 0.04, respectively.
In cultured blood cells, Crystagen raised lysate IL-18 to a printed median of 75.10 vs 39.06 pg/mL. The printed Crystagen interquartile range excludes its median.
Study notes · methods, sources and limitations
Participants or model Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Design Saline-controlled cultures from 15 donors, 0.4 µg/mL for 24 hours. Lysate and supernatant were analyzed separately.
Important limitations
- The volunteers donated blood and did not receive treatment. Culture concentrations cannot establish oral exposure or clinical effects. The Crystagen IL-18 median lies outside its printed interquartile interval. Some narrative percentages differ from ratios calculated from tabulated medians.
- The experiment measures cytokine concentrations after direct contact with cells. The clinical meaning and relevance to swallowing a capsule remain unknown.
Actual Problems of Humanities and Natural Sciences. 2016;12-3:97–100 · Original journal article
Comparison in people · 2018
Pinealon and Crystagen in a 28-rower study
Study of multiple preparations
- Hemoglobin
- 136.1 → 134.4 g/L active; 137.0 → 141.6 g/L controlSelected Table 6.6 means.
- Leukocytes
- 5.2 → 5.1 vs 5.9 → 5.8 ×10⁹/LActive versus ordinary-training group, Table 6.6.
- Oxidative markers
- Authors described lower lipid-peroxidation productsBiomarker results are separate from timed rowing.
The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.
Study notes · methods, sources and limitations
Participants or model 28 rowers aged 18–30, 18 men and 10 women. Active and ordinary-training groups n=14 each.
Design The authors describe stratified randomization and clinical, laboratory and oxidative-status measurements. Active supplement selection was individualized.
- Reported study exposure
- One oral capsule twice a day during meals for ten days in the active group. Individual capsule payload and allocation by preparation are not recoverable for each endpoint.
Important limitations
- The comparison group continued usual training. Heterogeneous formulations and small groups limit attribution. Participant overlap with Emirova’s older cytamin series remains uncertain.
Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182 · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
Comparison in people · 2012
Pinealon plus Crystagen in rhythmic gymnastics
Study of multiple preparations
- Morning recovery heart rate
- 83.8±1.5 → 74.2±2.5 beats/minCombination arm, p<0.05 within group. Comparison arm 86.6±3.2 → 88.4±3.6.
- Evening recovery heart rate
- 87.4±2.3 → 77.6±1.7 beats/minCombination arm, p<0.05 within group. Comparison arm 84.3±3.1 → 83.7±2.4.
- During routines and individual elements
- No statistically significant changes reportedTraining heart-rate measures are separate from performance judged in competition.
Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.
Study notes · methods, sources and limitations
Participants or model 20 elite female rhythmic gymnasts. Combination n=12; usual training n=8.
Design Author-described stratified assignment. Heart rate during training tasks and recovery, with other laboratory and self-reported outcomes.
- Reported study exposure
- One capsule of each oral product twice daily with meals for 20 days. The comparison was usual training without matched placebo.
Important limitations
- Both preparations were given together. Publications from the same group may repeat this cohort.
- The report cannot isolate Pinealon or Crystagen and does not demonstrate competitive benefit.
St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3 · St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3
Observational study · 2016
Personified prevention of diseases under the conditions of the Far North
Study of multiple preparations
- Sick-leave certificates
- 18 → 102014 → 2015; whole program
- Days unfit for work
- 119 → 602014 → 2015; whole program
- Seasonal morbidity
- No statistically reliable improvement reported
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
More reported outcomes
- Narrative/table discrepancy
- Narrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Study notes · methods, sources and limitations
Participants or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Design 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Important limitations
- One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.
Vrach. 2016;(6):64–66 · Journal publication
Research record · 2014
Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process
Study of multiple preparations
- Crystagen response
- B-cell activation reported; no aging-spleen cell renewal
- Other peptide responses
- Vilon: reduced T-helper apoptosis; Thymogen: B-cell proliferation with less apoptosis
Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model Experimental aging-spleen work; species and assay design not specified in the indexed abstract.
Design Experimental aging-spleen work; species and assay design not specified in the indexed abstract.
Important limitations
- The abstract does not establish the experimental model sufficiently to classify this as a human study or a specific animal/cell design. Commercial product equivalence is unverified.
Advances in gerontology = Uspekhi gerontologii 2014 · Journal publication
Performance research in context
- Compound class
- Peptide product / formulation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Institute report; independent peer review not established
Study methods
Randomization, blinding and product characterization unresolved
Independent replication
Independent replication not established in this collection
Source access
See source-specific abstracts, institute reports and explicit review scopes
Safety evidence
Systematic safety assessment incomplete
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Observational study · 2013
Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
Study notes and original source
Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency
Vladoniks, Vezugen and Kristagen as named in the paper. Branded oral preparations.
Hoàng Văn Huấn, Phạm Khắc Linh, Nguyễn Như Nghĩa, and colleagues · Journal of Tropical Science and Technology. 2013;(2):78–84.
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
Results and tables
Reported findings and study design
The researchers compared immunoglobulins and lymphocyte markers before and after the 20-day regimen. Tables show paired assessment denominators of 150. The reference laboratory column is a population benchmark.
Population or model 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
Dose, route and schedule
Vladoniks, Vezugen and Kristagen were taken orally for 20 days. The paper lists 0.2 g of each preparation. It does not give purified peptide content or capsule frequency.
Protocol source ↗ · Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| IgG | 1,202.27 → 1,445.20 mg/dL | Before and after the combination. · p<0.01 |
| CD4 cells | 501.96 → 569.33 cells/µL | p<0.01 |
| IgM | 126.56 → 132.46 mg/dL | p<0.01 |
| CD3 and CD8 cells | 963.01 → 1,088.78 and 389.72 → 438.10 cells/µL | p<0.01 and p<0.05, respectively |
| IgA, CD19 and CD4/CD8 ratio | No statistically significant change | p>0.05 |
| Author-defined overall outcome | 105/150 good, 45/150 fair | No untreated group for this rating. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
- Source reviewed
- Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.
Study limitations
- This was a before-and-after study of three products with no concurrent untreated group. Individual product effects and effects on infection risk remain uncertain.
- Program 33 reports 300 participants across two clinical series. The relationship between the two participant lists remains unverified.
Reviewed 2026-11-14.
Observational study · 2012
Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
Study notes and original source
Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans
Veziliut, Vezugen, Kristagen and Ventfort as named in the paper. Branded oral preparations.
Hoàng Văn Huấn, Phạm Khắc Linh, Nguyễn Như Nghĩa, and colleagues · Journal of Tropical Science and Technology. 2012;(1):85–93.
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
Results and tables
Reported findings and study design
Prospective, within-person comparison of urinary symptoms, quality of life and urine flow before and after adjunctive treatment. All reported denominators below are 150 at each assessment.
Population or model 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
Dose, route and schedule
The 20-day oral regimen lists Veziliut, Vezugen, Kristagen and Ventfort at 0.2 g each per day. These are amounts of the named products. The paper gives no purified peptide content.
Protocol source ↗ · Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| International Prostate Symptom Score | 20.94 ± 8.49 → 8.46 ± 2.78 | p<0.01 |
| Urinary flow | 4.9 ± 2.3 → 9.1 ± 2.5 mL/s | p<0.001 |
| Urinary symptom quality-of-life item | 4.10 ± 1.01 → 2.53 ± 0.61 | p<0.001 |
| Severe urinary symptoms | 61/150 → 14/150 | IPSS ≥20. The paper reports 40.7% → 9.3%. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
- Source reviewed
- Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.
Study limitations
- There was no concurrent untreated comparator or single-product arm. The results cover the combination.
- The tested Veziliut lot and its peptide content remain unclear. The two 150-person publications are part of the same parent program, and participant overlap remains unverified.
Reviewed 2026-11-14.
Lab research · 2016
Vladonix, Endoluten and other peptides in cultured human blood cells
In cultured blood cells, Crystagen raised lysate IL-18 to a printed median of 75.10 vs 39.06 pg/mL. The printed Crystagen interquartile range excludes its median.
Study notes and original source
Vladonix, Endoluten and other peptides in cultured human blood cells
Six separately assayed peptide preparations supplied by the Khavinson laboratory. · Original journal article
M. V. Maksimenya, E. V. Fefelova, A. S. Bykova · Actual Problems of Humanities and Natural Sciences. 2016;12-3:97–100
Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.
Results and tables
Reported findings and study design
Saline-controlled cultures from 15 donors, 0.4 µg/mL for 24 hours. Lysate and supernatant were analyzed separately.
Population or model Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Dose, route and schedule
Cells were exposed to 0.4 µg/mL of each preparation or volume-matched saline for 24 hours at 37 °C. Cytokines were measured by ELISA in cell lysates and culture supernatant.
Protocol source ↗ · Original journal PDF, methods, Table 1 and culture-supernatant results
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Vladonix · lysate IL-18 | 66.48 vs 39.06 pg/mL | Median with Vladonix versus saline. · p < 0.001 |
| Vladonix · lysate IL-1RA | 3,765 vs 5,228 pg/mL | Median with Vladonix versus saline. · p = 0.006 |
| Endoluten · lysate IL-18 and IL-4 | 65.11 vs 39.06 and 28.40 vs 12.24 pg/mL | Endoluten versus saline. · p = 0.02 and p < 0.001, respectively. |
| Crystagen and Cortexin · lysate IL-18 | 75.10 and 60.02 vs 39.06 pg/mL | Each preparation versus saline. Crystagen’s printed interval is inconsistent. · p = 0.004 and p = 0.04, respectively. |
| Vilon · lysate TNF-α and IL-1RA | 904.04 vs 598.05 and 4,056 vs 5,228 pg/mL | Vilon versus saline. · p = 0.045 and p = 0.02, respectively. |
| Epitalon · lysate IL-1RA | 4,346 vs 5,228 pg/mL | Epitalon versus saline. · p = 0.047 |
| Culture supernatant | Endoluten IL-18 +33.46% and Vilon TNF-α +41.13% | These were the only significant supernatant changes reported. Neither of the two Vladonix lysate findings was reported as significant in supernatant. · p = 0.02 and p = 0.035, respectively. |
Table 1 · cell-lysate cytokines
| Preparation | IL-18 (pg/mL) | TNF-α (pg/mL) | IL-4 (pg/mL) | IL-1RA (pg/mL) |
|---|---|---|---|---|
| Saline | 39.06 | 598.05 | 12.24 | 5,228 |
| Vladonix | 66.48* | 706.54 | 17.62 | 3,765* |
| Endoluten | 65.11* | 429.02 | 28.40* | 4,860 |
| Crystagen | 75.10* | 505.26 | 20.47 | 4,772 |
| Vilon | 34.74 | 904.04* | 9.96 | 4,056* |
| Epitalon | 30.62 | 548.00 | 9.50 | 4,346* |
| Cortexin | 60.02* | 693.00 | 15.04 | 4,921 |
Printed medians. Asterisks mark comparisons with saline at p < 0.05. The Crystagen IL-18 interquartile interval is printed as 66.46–70.62, which excludes the printed median.
The experiment measures cytokine concentrations after direct contact with cells. The clinical meaning and relevance to swallowing a capsule remain unknown.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
- Source reviewed
- Original journal PDF, methods, Table 1 and culture-supernatant results
Study limitations
- The volunteers donated blood and did not receive treatment. Culture concentrations cannot establish oral exposure or clinical effects.
- The Crystagen IL-18 median lies outside its printed interquartile interval. Some narrative percentages differ from ratios calculated from tabulated medians.
Reviewed 2026-11-13.
Comparison in people · 2018
Pinealon and Crystagen in a 28-rower study
The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.
Study notes and original source
Pinealon and Crystagen in a 28-rower study
· Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
Format: Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182 · Reviewed: Reported methods, results and evidence limitations
V. Kh. Khavinson et al. · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.
Results and tables
Reported findings and study design
The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.
The authors describe stratified randomization and clinical, laboratory and oxidative-status measurements. Active supplement selection was individualized.
Population or model 28 rowers aged 18–30, 18 men and 10 women. Active and ordinary-training groups n=14 each.
Dose, route and schedule
One oral capsule twice a day during meals for ten days in the active group. Individual capsule payload and allocation by preparation are not recoverable for each endpoint.
Protocol source ↗ · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hemoglobin | 136.1 → 134.4 g/L active; 137.0 → 141.6 g/L control | Selected Table 6.6 means. |
| Leukocytes | 5.2 → 5.1 vs 5.9 → 5.8 ×10⁹/L | Active versus ordinary-training group, Table 6.6. |
| Oxidative markers | Authors described lower lipid-peroxidation products | Biomarker results are separate from timed rowing. |
The comparison group continued usual training. Heterogeneous formulations and small groups limit attribution. Participant overlap with Emirova’s older cytamin series remains uncertain.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- 28 rowers aged 18–30, 18 men and 10 women. Active and ordinary-training groups n=14 each.
- Source reviewed
- Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
Study limitations
- The comparison group continued usual training. Heterogeneous formulations and small groups limit attribution. Participant overlap with Emirova’s older cytamin series remains uncertain.
Reviewed 2026-11-09.
Comparison in people · 2012
Pinealon plus Crystagen in rhythmic gymnastics
Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.
Study notes and original source
Pinealon plus Crystagen in rhythmic gymnastics
· St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3
Format: Reproduced original methodological report; comparison tables checked · Reviewed: Reported methods, results and evidence limitations
V. Kh. Khavinson, S. V. Trofimova, A. V. Trofimov, A. V. Dudkov, I. A. Viner, R. N. Terekhina, A. A. Lyshchev · St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3
Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.
Results and tables
Reported findings and study design
Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.
Author-described stratified assignment. Heart rate during training tasks and recovery, with other laboratory and self-reported outcomes.
Population or model 20 elite female rhythmic gymnasts. Combination n=12; usual training n=8.
Dose, route and schedule
One capsule of each oral product twice daily with meals for 20 days. The comparison was usual training without matched placebo.
Protocol source ↗ · Reproduced original methodological report; comparison tables checked
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Morning recovery heart rate | 83.8±1.5 → 74.2±2.5 beats/min | Combination arm, p<0.05 within group. Comparison arm 86.6±3.2 → 88.4±3.6. |
| Evening recovery heart rate | 87.4±2.3 → 77.6±1.7 beats/min | Combination arm, p<0.05 within group. Comparison arm 84.3±3.1 → 83.7±2.4. |
| During routines and individual elements | No statistically significant changes reported | Training heart-rate measures are separate from performance judged in competition. |
The report cannot isolate Pinealon or Crystagen and does not demonstrate competitive benefit.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- 20 elite female rhythmic gymnasts. Combination n=12; usual training n=8.
- Source reviewed
- Reproduced original methodological report; comparison tables checked
Study limitations
- Both preparations were given together. Publications from the same group may repeat this cohort.
Reviewed 2026-11-09.
Experiment described in a patent · 2011
Crystagen research trail: defined EDP peptide — US8057810B2
Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.
CD3-positive cells · 55.7 ± 2.6% after peptide-containing care versus 49.3 ± 2.2% conventional care; baseline 43.5 ± 2.3% · Immune-marker endpoint; significance annotation has an ambiguous comparator footnote
Study notes and original source
Crystagen research trail: defined EDP peptide — US8057810B2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Vladimir Khatskelevich Khavinson, Evgeny Iosifovich Grigoriev, Vladimir Victorivich Malinin, Galina Anatolievna Ryzhak · US8057810B2 · patent family 38314259
Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.
Results and tables
Reported patent results
Reported findings
Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.
EDP patent comparison in older adults aged 62–83: 38 receiving severity-adjusted adjunctive peptide and 32 conventional care.
Population or model EDP patent comparison in older adults aged 62–83: 38 receiving severity-adjusted adjunctive peptide and 32 conventional care.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CD3-positive cells | 55.7 ± 2.6% after peptide-containing care versus 49.3 ± 2.2% conventional care; baseline 43.5 ± 2.3% | Immune-marker endpoint; significance annotation has an ambiguous comparator footnote |
| CD4/CD8 ratio | 1.4 after peptide versus 1.2 conventional care; baseline 1.1 | Surrogate marker, not a disease or survival endpoint |
| B-cell marker | CD20 percentages 12.0 ± 0.7 versus 12.0 ± 0.4; baseline 12.3 ± 0.6 | No corresponding generalized improvement across all immune measures |
Incompletely specified allocation, severity-dependent treatment and marker endpoints limit inference. These observations concern defined EDP; commercial Crystagen equivalence remains unverified.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- EDP patent comparison in older adults aged 62–83: 38 receiving severity-adjusted adjunctive peptide and 32 conventional care.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The sequence-level connection does not authenticate the composition or efficacy of a commercial Crystagen product.
- Incompletely specified allocation, severity-dependent treatment and marker endpoints limit inference. These observations concern defined EDP; commercial Crystagen equivalence remains unverified.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Observational study · 2016
Personified prevention of diseases under the conditions of the Far North
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
Study notes and original source
Personified prevention of diseases under the conditions of the Far North
Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments · Journal publication
S. Trofimova, A. Trofimov, A. Koryakin, A. Chubukin, V. Ternovoy · Vrach. 2016;(6):64–66
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
Results and tables
Reported findings and study design
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Population or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Dose, route and schedule
One capsule of the assigned preparation daily for 20 days. Products were selected by risk assessment; all six products were not given to every participant.
Protocol source ↗ · Original PDF p.65
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sick-leave certificates | 18 → 10 | 2014 → 2015; whole program |
| Days unfit for work | 119 → 60 | 2014 → 2015; whole program |
| Seasonal morbidity | No statistically reliable improvement reported | |
| Narrative/table discrepancy | Narrative 43.4% decrease; Table 2 gives 119 → 60 days | Unresolved source discrepancy; not interchangeable figures |
Table 2 · Chronic-disease recurrence-related sick leave
| Measure | 2014 | 2015 |
|---|---|---|
| Sick-leave certificates | 18 | 10 |
| Days unfit for work | 119 | 60 |
Historical comparison for the shared 113-worker program. Not preparation-specific results.
One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
- Source reviewed
- Original publisher PDF methods and clinical table checked; table visually verified.
Study limitations
- One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.
Reviewed 2026-11-01.
Research record · 2014
Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process
Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.
Study notes and original source
Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Short-peptide experimental preparations; marketed-product equivalence unresolved · Journal publication
Сhervyakova NA, Linkova NS, Chalisova NI, Koncevaya EA, Trofimova SV, Khavinson VK · Advances in gerontology = Uspekhi gerontologii 2014
Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.
Results and tables
Reported findings and study design
Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.
Experimental aging-spleen work; species and assay design not specified in the indexed abstract.
Population or model Experimental aging-spleen work; species and assay design not specified in the indexed abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Crystagen response | B-cell activation reported; no aging-spleen cell renewal | |
| Other peptide responses | Vilon: reduced T-helper apoptosis; Thymogen: B-cell proliferation with less apoptosis |
The abstract does not establish the experimental model sufficiently to classify this as a human study or a specific animal/cell design. Commercial product equivalence is unverified.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Experimental aging-spleen work; species and assay design not specified in the indexed abstract.
- Source reviewed
- Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
- The abstract does not establish the experimental model sufficiently to classify this as a human study or a specific animal/cell design. Commercial product equivalence is unverified.
Reviewed 2026-11-01.
Comparison in people · 2006
Crystagen after radiation exposure: Medical Center clinical report
In the low-dose radiation subgroup, CD4-positive cells were 32.1% after Crystagen plus usual care versus 29.7% after usual care alone. The table marks the change from baseline, with no reported between-group test.
Study notes and original source
Crystagen after radiation exposure: Medical Center clinical report
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Oral Crystagen as described in the report · Institute report / commercial reproduction
Originating institute; report reproduced in commercial collection · Reports on clinical studies of CYTOMAX and CYTOGEN products; PDF page 109
In the low-dose radiation subgroup, CD4-positive cells were 32.1% after Crystagen plus usual care versus 29.7% after usual care alone. The table marks the change from baseline, with no reported between-group test.
Results and tables
Reported findings and study design
40 received Crystagen plus conventional therapy and 30 received conventional therapy alone. The reported oral regimen was one to three capsules two to three times daily for 15–20 days. Table 2 covers the low-dose radiation subgroup (20 treated, 15 comparator).
Population or model 70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CD4-positive cells in the low-dose radiation subgroup | 32.1 ± 1.8% with Crystagen vs 29.7 ± 2.4% with conventional care. Shared baseline 26.3 ± 2.4%. | The Crystagen value is marked p < 0.05 versus baseline. |
| CD3-positive cells in the low-dose radiation subgroup | 53.3 ± 2.2% with Crystagen vs 49.3 ± 2.3% with conventional care. Shared baseline 45.1 ± 2.1%. | The Crystagen value is marked p < 0.05 versus baseline. |
| IgG in the low-dose radiation subgroup | 15.2 ± 1.5 g/L with Crystagen vs 15.4 ± 1.4 g/L with conventional care. Shared baseline 15.1 ± 1.2 g/L. | The table gives no significance mark for IgG. |
The report uses a shared baseline and gives no direct between-group statistical test for these outcomes.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.
- Source reviewed
- Report reproduction, PDF pages 109–112. Methods and Tables 1–2.
Study limitations
- The report gives one shared baseline column and leaves allocation and masking unspecified.
- The low-dose radiation table covers 20 treated patients and 15 conventional-care patients.
- The clinical product is insufficiently characterized to establish equivalence with synthetic EDP.
Reviewed 2026-11-16.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗